Luteolin/ZnO nanoparticles attenuate neuroinflammation associated with diabetes via regulating MicroRNA-124 by targeting C/EBPA.
Enas Mahmoud MoustafaFatma S M MoawedDina F ElmaghrabyPublished in: Environmental toxicology (2023)
The results revealed that L/ZnO NPs were able to diminish lipid peroxidation, increase the activity of antioxidant enzymes, and reduce inflammation under oxidative stress. Consequently, it was able to reduce hyperglycemia, elevate insulin levels, and improve insulin resistance. Besides, L/ZnO NPs upregulate miR-124, reduce C/EBPA mRNA, increase BCl-2, and inhibit apoptosis. The results indicate that diabetes raises BBB permeability via tight junction protein decline, which is restored following L/ZnO NPs treatment. Luteolin/ZnO NPs regulate miR-124 and microglia polarization by targeting C/EBPA and are expected to alleviate inflammatory injury via modulation of the redox-sensitive signal transduction pathways. Luteolin/ZnO NPs have a novel target for the protection of the BBB and the prevention of neurological complications in diabetes.
Keyphrases
- oxidative stress
- room temperature
- type diabetes
- quantum dots
- glycemic control
- reduced graphene oxide
- visible light
- blood brain barrier
- cardiovascular disease
- insulin resistance
- cell proliferation
- long non coding rna
- diabetic rats
- oxide nanoparticles
- adipose tissue
- dna damage
- long noncoding rna
- inflammatory response
- endoplasmic reticulum stress
- binding protein
- gold nanoparticles
- metabolic syndrome
- single cell
- skeletal muscle
- risk factors
- fatty acid
- cell death
- ionic liquid
- spinal cord
- neuropathic pain
- weight loss
- endothelial cells
- lps induced
- polycystic ovary syndrome
- cerebral ischemia
- spinal cord injury
- subarachnoid hemorrhage
- smoking cessation